Autopsy report · NCT01813253
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 years 9 months before it stopped.
- 400 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Gastric Cancer; Gastroesophageal Junction Cancer
- Interventions
- Irinotecan; Nimotuzumab
- Participants
- 400
- Sites
- 37
- Countries
- Japan, South Korea, Taiwan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.